The US Food and Drug Administration (FDA) has approved the first virus-like particle (VLP) chikungunya vaccine PXVX0317 (VIMKUNYA™), for individuals aged 12 years and older, with Bavarian Nordic recently announcing its commercial launch.1,2 This approval addresses a critical unmet need for effective prevention of chikungunya virus infections in endemic regions. Prior to this, the only … Continue reading Chikungunya milestone: FDA approves first vaccine for teens and adults